Background-Although ␤-adrenergic receptor (AR) blockade therapy is beneficial in the treatment of heart failure, little is known regarding the transcriptional mechanisms underlying this salutary action. Methods and Results-In the present study, we screened mice overexpressing Gs␣, ␤ 1 AR, ␤ 2 AR, or protein kinase A to test if a common genomic pathway exists in different models with enhanced ␤-adrenergic signaling. In mice overexpressing Gs␣, differentially expressed genes were identified by mRNA profiling. In addition to well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and ␤-myosin heavy chain), uncoupling protein 2 (UCP2), a protein involved in the control of mitochondrial membrane potential, and four-and-a-half LIM domain protein-1 (FHL1), a member of the LIM protein family, were predicted to be upregulated. Upregulation of these genes was confirmed by quantitative reverse transcriptase-polymerase chain reaction at all time points tested during the development of cardiomyopathy in mice overexpressing Gs␣. In mice overexpressing ␤ 1 AR, ␤ 2 AR, or protein kinase A, increased UCP2 and FHL1 expression was also observed at the onset of cardiomyopathy. ␤AR blockade treatment reversed the cardiomyopathy and suppressed the increased expression of UCP2 and FHL1 in mice overexpressing Gs␣. Conclusions-UCP2 and FHL1 are important candidate genes that correlate with the development of ␤AR-induced cardiomyopathy in different mouse models with enhanced ␤AR signaling. In addition to preserving cardiac function, ␤AR blockade treatment also prevents the genomic regulation that correlates with the onset of heart failure.
T he deleterious effects of chronic ␤-adrenergic receptor (AR) stimulation in the heart have been documented in several mouse models. Transgenic mice overexpressing Gs␣ selectively in the myocardium develop cardiomyopathy with age, characterized by left ventricular (LV) dilation and hypertrophy, reduced LV function, fibrosis, apoptosis, and premature mortality. 1, 2 Mice overexpressing ␤ 1 AR, 3, 4 high levels of ␤ 2 AR, 5, 6 or protein kinase A (PKA) 7 also develop cardiomyopathy with aging. In patients with heart failure, ␤AR blockade therapy has been proven to be beneficial. 8 -11 However, little is known regarding the transcriptional mechanisms underlying this salutary action. In the present study, we screened different mouse models with enhanced ␤AR signaling to identify potential genomic targets of ␤AR blockade therapy. Using a sensitive, differential gene expression technology 12 to study gene expression profiles in Gs␣overexpressing mice, we identified unexpected genes that participate in the development of cardiomyopathy in these mice. Furthermore, we show that these candidate genes are involved in the development of cardiomyopathy in mice overexpressing ␤ 1 AR, ␤ 2 AR, or PKA. Most interestingly, the preservation of cardiac function brought by ␤AR blockade treatment in mice overexpressing Gs␣ normalizes the expression of uncoupling protein 2 (UCP2) and four-and-a-half LIM domain protein-1 (FHL1), showing that ␤-blockers alleviate the genomic dysregulation that accompanies heart failure.
Methods

Animals
Mice overexpressing Gs␣, 1 ␤ 1 AR, 3 ␤ 2 AR, 5 or PKA 7 have been previously described. Mice overexpressing ␤ 2 AR were originally described by Milano et al 5 and purchased from Jackson Laboratories (Bar Harbor, Maine). Genotyping 1, 3, 5, 7 and ␤AR blockade treatment 13 were carried out as described. Three to 9 animals have been studied in each group.
Differential Gene Expression Analysis by GeneCalling
Total RNA was prepared using Tri reagent (Sigma) from the hearts of 3-, 6-, 9-, 12-, and 15-month-old Gs␣-overexpressing mice or control littermates. Three animals per age group and genotype were analyzed individually. GeneCalling reactions 14 were performed as described in Figure 1 . Briefly, double-stranded DNA was generated from the pools of mRNA and digested with 96 pairs of restriction enzymes. The fragments were amplified by polymerase chain reaction (PCR) in the presence of fluorescent primers and separated according to their size by capillary electrophoresis. The different fragmentation profiles were compared to identify fragments with differential fluorescence, ie, expression level, between 2 samples. The identification of the gene corresponding to the fragment of interest relied on the size of the fragment and the 6-nucleotide sequence in 5Ј and 3Ј that corresponded to the restriction sites used to generate the fragment. Confirmation of the identity of a gene was done by competitive PCR.
Quantitative Reverse Transcriptase-PCR
Total RNA from transgenic mice and control littermates was prepared from frozen heart tissues using Tri reagent (Sigma). The mRNA of interest was reverse transcribed according to standard protocol. Real-time quantitative PCR (qPCR) (7700 Prizm, Perkin-Elmer/Applied Biosystems) was performed with specific primers and fluorogenic probes derived with FAM and TAMRA (Table 1) . 15, 16 Internal standards were prepared for each transcript from its PCRamplified cDNA after ligation of the T7 promoter. 16 Results were normalized to 36B4 16 or cyclophilin. 17
Statistics
Results obtained for transgenic mice were compared with those obtained for their age-matched control littermates using the unpaired Student t test.
Results
Genomic Profiling
We compared the gene expression profiles in mice overexpressing Gs␣ 1 and control littermates at 3, 6, 9, 12, and 15 months of age. Candidate genes with at least 2.5-fold predicted differential expression were identified ( Table 2 ). As expected, the transgene, Gs␣, was predicted to be high in Gs␣-overexpressing mice at all ages analyzed. In addition, genes of the following categories were predicted to have a modified expression pattern: extracellular matrix deposition (collagen III), metabolism (UCP2), transcription factors (FHL1 and cardiac ankyrin repeat protein [CARP]), stress (atrial natriuretic factor [ANF]), and myofilament (myosin heavy chain [MHC] and M-protein). Of particular interest, UCP2, a protein involved in the control of mitochondrial membrane potential, 18 and FHL1, a new member of the LIM protein family, 19 are known genes with unknown function in the heart. Interestingly, UCP2 and FHL1 expression were also found to increase during heart failure in different mouse models 20, 21 and in patients. 22, 23 These genes might therefore bring new insights into the understanding of the development of cardiomyopathy induced by chronic stimulation of ␤AR signaling.
Uncoupling Protein 2
After capillary electrophoresis, the peak corresponding to UCP2 was found to increase in 3-month-old Gs␣overexpressing mice ( Figure 2A ) and in 6-, 9-, 12-, and 15-month-old transgenic mice (not shown) compared with . cDNA fragments are amplified by PCR in the presence of fluorescent primers and separated according to their size by capillary electrophoresis. Differential fluorescence of the same fragment in 2 different samples suggests differential level of expression of the corresponding gene. Identification of the gene is based on the size of the fragment and the 6-nucleotide sequence in 5Ј and 3Ј that corresponds to the restriction sites used to generate the fragment. 14 Confirmation of a gene is done by competitive PCR. If correctly identified, the peak corresponding to the confirmed fragment is blunted (dotted line).
age-matched control mice. Competitive PCR was performed to confirm that the peak indeed corresponds to UCP2 ( Figure  2A ). Quantification of the changes in UCP2 expression during aging of Gs␣-overexpressing mice was done by qPCR. From 3 months of age onward, UCP2 expression was doubled in Gs␣-overexpressing mice compared with control littermates ( Figure 2B ).
Four-and-a-Half LIM Domain Protein-1
After capillary electrophoresis, the peak corresponding to FHL1 was increased in 3-month-old Gs␣-overexpressing mice ( Figure 3A ). This was also observed in 6, 9, 12 , and 15-month-old transgenic mice (not shown). After competitive PCR, the corresponding peak was blunted, confirming the identity of the gene ( Figure 3A) . Quantification of the changes in FHL1 expression during aging in Gs␣overexpressing mice was done by qPCR. From 3 months of age onward, a 2-to 3-fold increase in FHL1 expression was seen in Gs␣-overexpressing mice compared with control littermates ( Figure 3B ). In adult striated muscle, 3 isoforms of FHL have been described, FHL-1, -2, and -3. 24 We found increased expression of FHL1 in Gs␣-overexpressing mice, but no change in expression of FHL-2 or FHL-3 could be detected ( Figures 3B through 3D ).
Other Genes
Additional candidate genes were validated by qPCR during aging in Gs␣-overexpressing mice. As expected, expression of the transgene was high in Gs␣-overexpressing mice at all ages analyzed compared with control littermates ( Figure 4A ). The expression of markers of cardiac hypertrophy, ie, ANF, ␤-MHC, and CARP, were increased in 15-month-old Gs␣overexpressing mice ( Figures 4D through 4F ). Because changes in the expression of these genes occurred in old transgenic mice, they are likely to be a consequence and not the cause of the cardiomyopathy developed in these mice. The prediction of an upregulation of ␣-MHC (Table 2) did not reach a statistical significance after validation by qPCR (not shown). An upregulation of collagen type III was seen in Gs␣-overexpressing mice throughout aging and is related to the fibrosis seen in these mice 2 ( Figure 4B ). M-protein, which is part of the M-band, is the only gene found so far with decreased expression in mice overexpressing Gs␣ ( Figure 4C ).
␤AR Blockade
To test whether the increased expression of UCP2 and FHL1 seen in Gs␣-overexpressing mice is attributable directly to the chronic stimulation of ␤AR signaling in these mice, a NP indicates no prediction for the gene at the indicated age. The complete list of genes is provided in the online data supplement available at http://www.circulationaha.org. ␤AR-blockade experiment was designed. We previously showed that ␤AR blockade was sufficient to arrest myocyte damage and preserve cardiac function in mice overexpressing Gs␣. 13 The increased expression of UCP2 and FHL1 seen in Gs␣-overexpressing mice in the absence of treatment was decreased significantly by the ␤AR-blockade treatment, as measured by qPCR ( Figures 5A and 5B ). Because ␤AR blockade can decrease ␣-MHC expression, 25 we verified that the treatment did not affect the expression of the Gs␣ transgene, which is under the control of the ␣-MHC promoter 1 (Figure 5C ).
Common Genomic Pathway
Increased expression of UCP2 and FHL1 in Gs␣overexpressing mice suggests that these genes might play a role in the development of the cardiomyopathy seen in these mice. To test if a common transcriptional pathway leads to cardiomyopathy in other models of enhanced ␤AR signaling, we studied the expression of UCP2 and FHL1 in mice overexpressing ␤ 1 AR, 3,4 ␤ 2 AR, 5, 6 or PKA. 7 In ␤ 1 AR transgenic mice, overexpression at 15 times endogenous ␤AR levels is sufficient to lead to increased contractility at a young age (7 weeks) and to result in cardiomyopathy with aging (30 weeks). 3 Expression of UPC2 ( Figure 6A ) and FHL1 ( Figure 6B ) was significantly increased at both time points in ␤ 1 AR-overexpressing mice compared with control littermates.
In a thorough study analyzing several lines of ␤ 2 ARoverexpressing mice, Liggett et al 6 reported that cardiomyopathy is seen only with high (Ͼ100-fold) levels of ␤ 2 AR overexpression and develops more slowly than in mice overexpressing ␤ 1 AR. The severity of the cardiomyopathy and mortality correlates with the expression level of ␤ 2 AR. Milano et al 5 reported another line of ␤ 2 AR-overexpressing mice that we obtained through Jackson Laboratories for this study. These mice have a 200-fold overexpression of ␤ 2 AR in the heart. 5 At 3 months of age, they displayed enhanced contractility (ejection fraction: wild-type, 69Ϯ2%; transgenic, 75Ϯ1%; PϽ0.05; fraction shortening: wild-type, 33Ϯ1%; transgenic, 37Ϯ1%; PϽ0.05) and no evidence of cell death. 5 At 12 months of age, however, these ␤ 2 ARoverexpressing mice showed a significant decrease in left ventricular function (ejection fraction: young transgenic, 75Ϯ1%; old transgenic, 59Ϯ2%; PϽ0.05; fraction shorten- ing: young transgenic, 37Ϯ1%; old transgenic, 26Ϯ2%; PϽ0.05), whereas no significant change was seen with aging in control littermates. UCP2 expression was unchanged in 3-month-old ␤ 2 AR-overexpressing mice compared with control littermates but dramatically increased with aging in the transgenic mice ( Figure 6C ). FHL1 was significantly increased at both ages ( Figure 6D ).
Mice overexpressing PKA show dilated cardiomyopathy and sudden death independent of more proximal events in ␤AR signaling. 7 Expression of UCP2 and FHL1 were significantly increased in 3-month-old PKA-overexpressing mice compared with control littermates (Figures 6E and 6F ).
Discussion
In the present study, we used different mouse models with enhanced ␤AR signaling to identify potential genomic targets of ␤AR blockade therapy and found that UCP2 and FHL1, two genes with unknown function in the heart, might play an important role in the development of ␤AR-induced cardiomyopathy.
Uncoupling proteins received their name from their role in uncoupling respiration from ATP production, generating heat in brown adipose tissue (UCP1) and skeletal muscle (UCP3). 18 A potential role for UCP2, supported by the corresponding knockout mice, 26 is the regulation of reactive oxygen species (ROS) production. Reduction of ROS would be protective but would come at the cost of increased uncoupling activity that might compromise the mitochondrial membrane potential, eventually leading to cell death. 18, 27 Enhanced UCP2 expression was found in the heart of rats after prolonged thyroid hormone treatment and is thought to have a detrimental effect on cardiac function in that model. 21 In mice overexpressing Gs␣ ( Figure 2B ) or ␤ 1 AR ( Figure  6A ), UCP2 is upregulated before the development of cardiomyopathy and throughout aging, suggesting that it can play a role in the transition of phenotype between young and old transgenic mice. In young transgenic mice, increased expression of UCP2 might decrease the amount of ROS and therefore play a protective role. As mice age, sustained uncoupling might damage mitochondrial membrane, leading to apoptosis. No change in UCP2 expression was detected in young ␤ 2 AR-overexpressing mice, suggesting that in this model, UCP2 might not be a cause of the cardiomyopathy developed with aging ( Figure 6C ).
FHL proteins are new members of the LIM-only protein family. The pattern of expression of FHL1 suggests an important role for FHL1 in the heart during development 20 and cardiomyopathy. 20, 23 In this study, we show that FHL1, but not FHL2 or FHL3, is upregulated in mice overexpressing Gs␣ (Figure 3 ). FHL1 expression, but not that of FHL2 or FHL3, also was found to increase in 2 mouse models with cardiac hypertrophy and dilated cardiomyopathy 20 and in hypertrophic and failing hearts from patients. 22, 23 FHL1 is upregulated in all the models tested with chronic stimulation of ␤AR signaling before the development of cardiomyopathy and throughout aging, suggesting that it might play a role in the transition of phenotype between young and old transgenic mice.
Interestingly, the time course of UCP2 upregulation is different in mice overexpressing ␤ 1 AR and ␤ 2 AR. Although both ␤ 1 AR and ␤ 2 AR couple to the Gs␣/adenylyl cyclase pathway, major differences exist between these 2 receptors, 28,29 reflected by differential actions on cardiac Ca 2ϩ handling, contractility, cAMP accumulation (reviewed in Xiao et al 30 ) , and apoptosis. 31 In mice overexpressing ␤ 1 AR and ␤ 2 AR, there are also differences in the time and dosage required to develop cardiomyopathy. ␤ 1 AR-overexpressed mice develop cardiomyopathy early, whereas cardiomyopathy in ␤ 2 AR-overexpressed mice develops late, unless the receptors are overexpressed orders of magnitude greater than ␤ 1 AR. 6 This timing difference is reflected by the different time course of upregulation of UCP2 in both models: UCP2 expression is increased as early as at 7 weeks of age in ␤ 1 AR-overexpressed mice, whereas in ␤ 2 AR-overexpressed mice, it is unchanged at 3-months of age but increases at 12 months. This suggests that UCP2 is an important marker of the development of cardiomyopathy in these models. FHL1 expression is increased at both ages in ␤ 2 AR-overexpressing mice, suggesting that modification of the expression of transcription factors precedes the modification of the expression of target proteins, such as UCP2.
In conclusion, we used genomic profiling to identify unexpected genes that might play a role in the development of cardiomyopathy induced by chronic ␤AR signaling. We identified UCP2 and FHL1 as important candidate genes that correlate with the development of ␤AR-induced cardiomyopathy in different animal models. Increased UCP2 expression results specifically from a ␤ 1 AR-Gs␣-PKA pathway. The upregulation of UCP2 and FHL1 in mice overexpressing Gs␣ was reversed by ␤AR-blockade treatment, suggesting that these 2 genes could be direct targets for the treatment of heart failure. 
